Connor Clark & Lunn Increases Holdings in Puma Biotechnology by 32.3%, JPMorgan's Holdings Increase by 169.5%

Summary

Connor Clark & Lunn Investment Management Ltd. increased its holdings in Puma Biotechnology, Inc. (NASDAQ: PBYI) by 32.3% in the fourth quarter, now holding 487,368 shares valued at $1.49 million. Other hedge funds also increased their positions, with JPMorgan Chase’s holdings increasing by 169.5%. Puma’s stock opened at $3.45, with a market cap of $171.16 million. The company reported last quarter earnings per share (EPS) of $0.39, exceeding expectations. Analysts forecast this fiscal year’s EPS to be $0.31, with HC Wainwright giving a buy rating and a target price of $7.00.Market Beat

Impact Analysis

The event primarily affects Puma Biotechnology at the company level, highlighting increased investment interest due to positive earnings performance. The increase in holdings by Connor Clark & Lunn and other funds suggests confidence in Puma’s future prospects, potentially driving up stock prices due to demand. The buy rating and target price indicate analyst optimism. For JPMorgan Chase, the event involving Northern Trust Corp and Capital Research Global Investors shows increased institutional interest, impacting the company at the public institution level. This institutional support could stabilize or enhance JPMorgan Chase’s stock value. Investment opportunities arise from potential appreciation in Puma Biotechnology’s stock if earnings continue to exceed expectations, presenting a buy opportunity based on analyst ratings.Market Beat+ 2